Clinical Trials · NCT07046273
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Enrollment
- 496
- Start date
- Aug 2025
- Locations
- See registry
- Primary endpoint
- Change in HbA1c from baseline